PC
MRNA icon

PointState Capital’s Moderna MRNA Stock Holding History

PointState Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,990
Closed -$1.01M – 110
2021
Q4 		$1.01M Buy
3,990
+690
+21% +$202K 0.02% 111
2021
Q3 		$1.27M Sell
3,300
-6,700
-67% -$2.47M 0.02% 125
2021
Q2 		$2.35M Buy
+10,000
New +$1.79M 0.04% 108
2021
Q1 		– Sell
-15,000
Closed -$1.57M – 151
2020
Q4 		$1.57M Hold
15,000
– – 0.03% 116
2020
Q3 		$1.06M Sell
15,000
-20,000
-57% -$1.39M 0.03% 95
2020
Q2 		$2.25M Buy
+35,000
New +$1.92M 0.07% 71

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PointState Capital's MRNA Position: Q1 2022 in Review

PointState Capital sold out of Moderna (MRNA) in Q1 2022, closing a stake of 3,990 shares — an estimated $1.01M sold.

PointState Capital first reported a position in MRNA in Q2 2020 and held it in 6 quarters. The position peaked at $2.35M in Q2 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • PointState Capital reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • PointState Capital sold 3,990 Moderna shares in Q1 2022, an estimated $1.01M.
  • PointState Capital first reported a position in Moderna in Q2 2020 and held it in 6 quarters.
  • PointState Capital's Moderna position peaked at $2.35M in Q2 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.